Article
Chemistry, Medicinal
Reinier Cardentey Sanchez, Amado Diaz de la Fe, Alejandro Pelaez Suarez, Dayme Grass, Teresa Morgado Vega, Armando Sanchez Canal, Dario Siniscalco, Maria de los Angeles Robinson Agramonte
Summary: Multiple sclerosis is an autoimmune neurodegenerative disease that lacks a curative treatment. The use of interferon beta 1a has shown safety and efficacy in treating relapsing remitting MS patients, with significant reductions in attacks, disability scale scores, and lesions observed.
DRUG DEVELOPMENT RESEARCH
(2021)
Article
Biology
Cristina-Florentina Plesa, Diana Maria Chitimus, Carmen Adella Sirbu, Monica Marilena Tantu, Minerva Claudia Ghinescu, Daniela Anghel, Florentina Ionita-Radu
Summary: This case study describes a particular association between the remission phase of multiple sclerosis and the violent onset of interferon-induced thrombotic thrombocytopenic purpura.
Article
Clinical Neurology
Wolf A. Lagreze, Sebastian Kuechlin, Gabriele Ihorst, Birgit Grotejohann, Flemming Beisse, Martin Volkmann, Sven P. Heinrich, Philipp Albrecht, Judith Ungewiss, Michael Woerner, Martin J. Hug, Sebastian Wolf, Ricarda Diem
Summary: The study showed that erythropoietin as an adjunct to corticosteroids did not provide neuroprotection in the visual pathways after optic neuritis. Future research could focus on modified erythropoietin administration, assess its efficacy independent of corticosteroids, and investigate whether it affects the conversion of optic neuritis to multiple sclerosis.
Review
Pharmacology & Pharmacy
Yahiya Y. Syed
Summary: Alemtuzumab is an effective treatment option for patients with highly active RRMS, with maintained treatment benefits over up to 9 years. It has an acceptable tolerability profile and convenient treatment regimen.
Article
Clinical Neurology
Judith Bellmann-Strobl, Friedemann Paul, Jens Wuerfel, Jan Doerr, Carmen Infante-Duarte, Elmira Heidrich, Benedict Koertgen, Alexander Brandt, Caspar Pfuller, Helena Radbruch, Rebekka Rust, Volker Siffrin, Orhan Aktas, Christoph Heesen, Juergen Faiss, Frank Hoffmann, Mario Lorenz, Benno Zimmermann, Sergiu Groppa, Klaus-Dieter Wernecke, Frauke Zipp
Summary: In patients with RRMS, adding oral EGCG to GA did not show superiority over placebo in affecting MRI and clinical disease activity. Despite indications of EGCG bioavailability, it did not influence immune parameters. However, treatment with up to 800 mg of EGCG daily was safe and well tolerated.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Medicine, General & Internal
Patrick K. A. Kearns, Sarah J. Martin, Jessie Chang, Rozanna Meijboom, Elizabeth N. York, Yingdi Chen, Christine Weaver, Amy Stenson, Katarzyna Hafezi, Stacey Thomson, Elizabeth Freyer, Lee Murphy, Adil Harroud, Peter Foley, David Hunt, Margaret McLeod, Jonathon O'Riordan, F. J. Carod-Artal, Niall J. J. MacDougall, Sergio E. Baranzini, Adam D. Waldman, Peter Connick, Siddharthan Chandran
Summary: This study aims to explore the pathobiology and determinants of disease heterogeneity in multiple sclerosis (MS) by integrating clinical phenotyping, imaging, genetics, and biomarkers. Recruitment, baseline assessment, and one-year follow-up have been completed. Longer-term follow-up is planned.
Article
Clinical Neurology
Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L. Arnold, Kivilcim Guecueyener, Kumaran Deiva, Natalia Skripchenko, Li-Ying Cui, Stephane Saubadu, Wenruo Hu, Myriam Benamor, Annaig Le-Halpere, Philippe Truffinet, Marc Tardieu
Summary: The TERIKIDS study investigated the safety and efficacy of teriflunomide in children with relapsing multiple sclerosis. The study showed that teriflunomide could significantly reduce the risk of focal inflammatory activity in pediatric patients with relapsing multiple sclerosis compared to placebo.
Article
Critical Care Medicine
Andre C. Kalil, Aneesh K. Mehta, Thomas F. Patterson, Nathaniel Erdmann, Carlos A. Gomez, Mamta K. Jain, Cameron R. Wolfe, Guillermo M. Ruiz-Palacios, Susan Kline, Justino Regalado Pineda, Anne F. Luetkemeyer, Michelle S. Harkins, Patrick E. H. Jackson, Nicole M. Iovine, Victor F. Tapson, Myoung-don Oh, Jennifer A. Whitaker, Richard A. Mularski, Catharine Paules, Dilek Ince, Jin Takasaki, Daniel A. Sweeney, Uriel Sandkovsky, David L. Wyles, Elizabeth Hohmann, Kevin A. Grimes, Robert Grossberg, Maryrose Laguio-Vila, Allison A. Lambert, Diego Lopez de Castilla, EuSuk Kim, LuAnn Larson, Claire R. Wan, Jessica J. Traenkner, Philip O. Ponce, Jan E. Patterson, Paul A. Goepfert, Theresa A. Sofarelli, Satish Mocherla, Emily R. Ko, Alfredo Ponce de Leon, Sarah B. Doernberg, Robert L. Atmar, Ryan C. Maves, Fernando Dangond, Jennifer Ferreira, Michelle Green, Mat Makowski, Tyler Bonnett, Tatiana Beresnev, Varduhi Ghazaryan, Walla Dempsey, Seema U. Nayak, Lori Dodd, Kay M. Tomashek, John H. Beigel
Summary: This study compared the efficacy of interferon beta-1a in combination with remdesivir versus remdesivir alone in hospitalised COVID-19 patients. The results showed no significant difference in time to recovery and mortality rate between the interferon beta-1a plus remdesivir group and the placebo plus remdesivir group, with patients requiring high-flow oxygen at baseline having poorer outcomes after interferon beta-1a treatment.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Clinical Neurology
J. William L. Brown, Nick G. Cunniffe, Ferran Prados, Baris Kanber, Joanne L. Jones, Edward Needham, Zoya Georgieva, David Rog, Owen R. Pearson, James Overell, David MacManus, Rebecca S. Samson, Jonathan Stutters, Charles Ffrench-Constant, Claudia A. M. Gandini Wheeler-Kingshott, Carla Moran, Paul D. Flynn, Andrew W. Michell, Robin J. M. Franklin, Siddharthan Chandran, Daniel R. Altmann, Declan T. Chard, Peter Connick, Alasdair J. Coles
Summary: This study aimed to evaluate the safety and efficacy of non-selective retinoid X receptor agonist bexarotene in promoting remyelination in patients with multiple sclerosis. The results showed that the bexarotene treatment group had more adverse events and poor efficacy outcome, therefore not recommended for the treatment of multiple sclerosis.
Article
Medicine, General & Internal
Sandra D. Cassard, Kathryn C. Fitzgerald, Peiqing Qian, Susan A. Emrich, Christina J. Azevedo, Andrew D. Goodman, Elizabeth A. Sugar, Daniel Pelletier, Emmanuelle Waubant, Ellen M. Mowry
Summary: The VIDAMS trial aimed to determine if high dose versus low dose vitamin D3 supplementation reduces the risk of clinical relapse in MS patients. The study found that high dose vitamin D3 supplementation did not reduce the risk of relapse in RRMS patients, suggesting that prescribing higher doses of vitamin D may not be beneficial for modifying the course of RRMS.
Article
Critical Care Medicine
Phillip D. Monk, Richard J. Marsden, Victoria J. Tear, Jody Brookes, Toby N. Batten, Marcin Mankowski, Felicity J. Gabbay, Donna E. Davies, Stephen T. Holgate, Ling-Pei Ho, Tristan Clark, Ratko Djukanovic, Tom M. A. Wilkinson
Summary: The study evaluated the efficacy and safety of using interferon beta-1a to treat COVID-19, with results showing that patients who received treatment had higher and faster recovery rates, providing potential evidence for further clinical trials.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Clinical Neurology
Anders Svenningsson, Thomas Frisell, Joachim Burman, Jonatan Salzer, Katharina Fink, Susanna Hallberg, Joakim Hambraeus, Markus Axelsson, Faiez Al Nimer, Peter Sundstrom, Martin Gunnarsson, Rune Johansson, Johan Mellergard, Igal Rosenstein, Ahmad Ayad, Irina Sjoblom, Anette Risedal, Pierre de Flon, Eric Gilland, Jonas Lindeberg, Fadi Shawket, Fredrik Piehl, Jan Lycke
Summary: Rifund-MS study provides evidence that rituximab is superior to dimethyl fumarate in preventing relapses in patients with early relapsing-remitting multiple sclerosis. Adverse events such as infusion reactions and gastrointestinal reactions were observed, but there were no safety concerns.
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Clinical Neurology
C. Louapre, M. Rosenzwajg, M. Golse, A. Roux, F. Pitoiset, L. Adda, N. Tchitchek, C. Papeix, E. Maillart, A. Ungureanu, F. Charbonnier-Beaupel, D. Galanaud, J. C. Corvol, E. Vicaut, C. Lubetzki, D. Klatzmann
Summary: The effect of low-dose interleukin-2 (IL2(LD)) treatment on regulatory T cells (Tregs) in multiple sclerosis (MS) patients was modest and delayed, compared to other autoimmune diseases. Larger studies with increased dosages and/or modified modalities of administration are needed.
JOURNAL OF NEUROLOGY
(2023)
Article
Medicine, General & Internal
Joakim Steiness, Daniel Hagi-Pedersen, Troels Haxholdt Lunn, Martin Lindberg-Larsen, Ben Kristian Graungaard, Lars Hyldborg Lundstrom, Peter Lindholm, Stig Brorson, Manuel Josef Bieder, Torben Beck, Michael Skettrup, Adam Gregers von Cappeln, Kasper Hojgaard Thybo, Kasper Smidt Gasbjerg, Soren Overgaard, Janus Christian Jakobsen, Ole Mathiesen
Summary: This study aims to investigate the benefits and harms of different combinations of paracetamol, ibuprofen, and dexamethasone following total hip arthroplasty. The randomized controlled trial will be conducted at multiple Danish hospitals, with follow-up periods of 90 days and 1 year.
